Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hyaluronic Acid Is a Biomarker for Allograft Dysfunction and Predicts 1-Year Graft Loss After Liver Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Donor Smoking and Older Age Increases Morbidity and Mortality After Lung Transplantation

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Donor Kidney With Renal Cell Carcinoma Successfully Treated With Radiofrequency Ablation: A Case Report

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. First Report of Lung Transplantation in a Patient With Active Pulmonary Mycobacterium simiae Infection

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Uafklaret dyspnø.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hjertesygdomme

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearchpeer-review

View graph of relations
A 44-year-old woman underwent left single-lung transplantation for end-stage emphysema due to α1-antitrypsin deficiency in January 2010. Cyclosporine, azathioprine, and prednisolone were administered for immunosuppression and antithymocyte globulin for induction therapy at the time of transplantation. Routine examination of a lung biopsy, 4 months after transplantation, showed nonspecific, diffuse interstitial inflammation with alveolar septal fibrosis. The patient's clinical status and imaging studies, consistent with nonspecific interstitial pneumonitis, which was considered as signs of acute rejection, worsened within 2 weeks, despite high-dose steroids, change of calcineurin inhibitor, and plasmapheresis. Within a few days after a single, 10-mg, intravenous dose of alemtuzumab, the patient's health improved markedly. She has remained stable for 4 months on a standard, ambulatory, posttransplant antirejection drug regimen. We have since successfully treated with alemtuzumab three additional patients who developed interstitial lung injury after lung transplantation, who are also summarized in this report.
Original languageEnglish
JournalTransplantation Proceedings
Volume43
Issue number5
Pages (from-to)1868-70
Number of pages3
ISSN0041-1345
DOIs
Publication statusPublished - 2011

    Research areas

  • Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Neoplasm, Female, Humans, Injections, Intravenous, Lung Diseases, Interstitial, Lung Transplantation, Treatment Outcome

ID: 33266711